Evidence map›Paper›PMID 40178153›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

A Novel Theranostic Strategy for Malignant Pulmonary Nodules by Targeted CECAM6 with

Chongyang Chen, Keying Zhu, Jing Wang, Donghui Pan, Xinyu Wang, Yuping Xu, Junjie Yan, Lizhen Wang, Min Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. A Novel Theranostic Strategy for Malignant Pulmonary Nodules by Targeted CECAM6 withAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chongyang ChenNHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, 214063, China.
Keying ZhuNHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, 214063, China.
Jing WangWuxi Xishan NJU Institute of Applied Biotechnology, Anzhen Street, Xishan District, Wuxi, 214101, China.
Donghui PanNHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, 214063, China.
Xinyu WangNHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, 214063, China.
Yuping XuNHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, 214063, China.
Junjie YanNHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, 214063, China.
Lizhen WangNHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, 214063, China.
Min YangNHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, 214063, China.ORCID https://orcid.org/0000-0001-6976-8526

Funding

Capacity Enhancement Project of Jiangsu Provincial Health Commission ZDXYS202211Jiangsu commission of health foundation K2024088Jiangsu commission of health foundation M2022090Jiangsu Provincial Natural Science Foundation BK20230180Natural Science Foundation of China 82071221Natural Science Foundation of China 82301630Wuxi Science and Technology Development fund Y20222027
6 · The paper itself

Abstract

Lung adenocarcinoma (LUAD) constitutes a major cause of cancer-related fatalities worldwide. Early identification of malignant pulmonary nodules constitutes the most effective approach to reducing the mortality of LUAD. Despite the wide application of low-dose computed tomography (LDCT) in the early screening of LUAD, the identification of malignant pulmonary nodules by it remains a challenge. In this study, CEACAM6 (also called CD66c) as a potential biomarker is investigated for differentiating malignant lung nodules. Then, the CEACAM6-targeting monoclonal antibody (mAb, tinurilimab) is radiolabeled with

Indexed as

Adenocarcinoma of LungAntibodies, MonoclonalCell Adhesion MoleculesLung NeoplasmsMultiple Pulmonary NodulesRadioisotopesTheranostic NanomedicineZirconiumAnimalsAntibodies, Monoclonal, HumanizedCell Line, TumorFemaleHumansIodine RadioisotopesMiceAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedCell Adhesion MoleculesIodine RadioisotopesRadioisotopesZirconiumZirconium-8989Zr/131I‐labeled tinurilimabCEACAM6LUADmalignant pulmonary nodulesPET/MRtheranostics

Identifiers

PMID40178153
PMCPMC12140296

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.